The Gaithersburg, MD-based biotech develops therapies for autoimmune and severe inflammatory disorders. Lead candidate is inebilizumab, a CD19-targeting humanized monoclonal antibody for the potential treatment of a rare autoimmune disease called neuromyelitis optica spectrum disorder. Its current pipeline of five molecules was acquired from AZN’s MedImmune.
2019 Financials (6 mo.): Operating Expenses: $160.3M; Net Loss: ($159.5M); Cash Burn: ($3.3M).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.